New trial
Spotlight
Phase 1/2 TNG462 PRMT5 inhibitor trial with KRAS inhibitor combinations.
- Trial ID
- NCT06922591 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Location
- 2 Locations
- Published in
- New in Oncology - July 3, 2025
This open-label, multicenter trial evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral TNG462 combined with investigational KRAS agents RMC-6236 or RMC-9805 in patients with pancreatic or non-small cell lung cancer exhibiting MTAP loss and RAS mutation. Conducted in Irving and Fairfax, the study is sponsored by Tango Therapeutics.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings